CLOs on the Move


 
Embody, Inc. is a commercial-stage company pioneering the next generation regenerative platform for the repair of tendon and ligament injuries with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brianna Schehr
Director of Quality, Regulatory and Clinical Affairs Profile

Similar Companies

Arizant Healthcare, a 3M company

Arizant Inc.'s main subsidiary, Arizant Healthcare Inc., pioneered the concept of forced-air patient warming with the introduction of Bair Hugger therapy in 1987. Fueled by the success of Bair Hugger therapy, the company has continuously displayed

Digital Transcription System

Digital Transcription System is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acuderm

Acuderm is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GN Otometrics North America

GN Otometrics North America is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bardy Diagnostics

Bardy Diagnostics, Inc. (bardydx.com) has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM™) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. Developed on the principle that non-invasive cardiac monitoring should provide an excellent quality atrial signal, the CAM is designed to be placed along the sternum—over the heart— to optimize P-wave signal capture. The result is improved ECG resolution, providing more information about the heart rhythm which may lead to more clinically actionable diagnoses.